NCT05917964View on ClinicalTrials.gov

A Food Effect Study of LP-168 Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

August 21, 2023

Study Completion Date

August 21, 2023

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

LP-168 tablet

LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration

Trial Locations (1)

310003

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Guangzhou Lupeng Pharmaceutical Company LTD.

INDUSTRY